Form 4: Akoya Biosciences Executive Receives Stock Options and Restricted Stock Units

Niro Ramachandran, Chief Business Officer of Akoya Biosciences, acquired stock options and restricted stock units, and had shares withheld for taxes.

Summary

• On February 22, 2024, Niro Ramachandran, the Chief Business Officer of Akoya Biosciences, Inc., was granted 35,000 restricted stock units.
• These restricted stock units will vest in four equal annual installments starting March 1, 2025.
• Each restricted stock unit represents the right to receive one share of Akoya Biosciences common stock.
• On March 1, 2024, 2,305 shares of common stock were withheld to cover taxes on a previously granted restricted stock unit award.
• Also on February 22, 2024, Ramachandran was granted options to purchase 70,000 shares of Akoya Biosciences common stock at an exercise price of $5.35.
• 25% of these options will vest on February 22, 2025, with the remainder vesting in 36 equal monthly installments beginning on March 22, 2025.

Sentiment

Score: 6

Explanation: The document reflects standard executive compensation practices, which is neutral to slightly positive as it incentivizes management.

Positives

• The grant of restricted stock units and stock options to the Chief Business Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in biotech, similar to companies like NanoString Technologies and Personalis.
• Vesting schedules are also typical, often spanning 3-4 years to incentivize long-term performance, aligning with industry norms.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates